Our results indicate that by incorporating two cooperating anticancer chemical groups into the same compound, dual-targeting drugs with higher efficacy can be generated.
The transfected and untransfected cells showed no significant change in the percentage of cell survival upon the 3 anticancer drugs treatment groups (vincristine: P value = 0.77; etoposide: P value = 0.20; and carboplatin: P value = 0.71) (Fig. 8A C).
Thirty-three patientshoweded high sensitivity (T/C ratio <60%%) to at least one type of anticancer agent (sensitive group), and 31 showed low sensitivity (T/C ratio ≥60%%) to all agents (resistant group).
Investigations of the complex biosyntheses of the angucycline group anticancer drugs landomycin, jadomycin and gilvocarcin revealed that in vivo and in silico studies were insufficient to delineate the true biosynthetic sequence of events.
Resting tumor cells display enhanced treatment resistance compared with actively cycling tumor cells, as several groups of anticancer drugs directly target the active cell cycle.
It was through his efforts that the NCI was able to convince the FDA to take a more open view on approving IND applications for anticancer drugs from expert groups in Europe and the UK.
In light of the optimistic results of the above-mentioned clinical studies, supported by promising results in improved IL-12-based preclinical models of tumor immunotherapy, there is hope that IL-12 will join (ultimately!) the armamentarium of anticancer agents and selected groups of patients will benefit from the treatment.
This prodrug comprises three parts: coumarin as the fluorophore and the cleavable architecture, chlorambucil as the anticancer drug, and acetyl group as the enzyme-responsive unit.
Pre-clinical and early clinical data for one of these CMTs, COL-3 (formerly CMT-3) indicate considerable potential for this group of anticancer agents.
The average lifespan of the mice treated by the above combined therapy is beyond 40 days, which are ∼2.6 times longer than that (15 days) observed from the anticancer drug doxorubicin-treated group.
